Federal Health Agency Identifies Three Candidate Treatments for Osteoarthritis

The Advanced Research Projects Agency for Health (ARPA-H) has selected five research teams to develop regenerative treatments for osteoarthritis under its Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program [1]. The effort targets three distinct therapeutic approaches: injectable bone regeneration, injectable cartilage regeneration, and replacement joints grown from a patient's own cells [2]. With contracts totaling over $70 million across the lead teams alone, the federal government is making its largest coordinated investment in osteoarthritis reversal to date — for a disease that affects 32.5 million American adults and costs the U.S. economy an estimated $136.8 billion per year [3].

The ambition is significant. So is the track record of failure. No disease-modifying osteoarthritis drug (DMOAD) has ever received FDA approval [4]. The question facing patients, researchers, and policymakers is whether NITRO represents a genuine inflection point or another chapter in a long history of unmet promises.

The Scale of the Problem

Osteoarthritis is the most common form of arthritis and a leading cause of chronic pain and disability worldwide. In the United States, 32.5 million adults carry the diagnosis, and 53.2 million have some form of arthritis — roughly one in five adults [3]. The disease breaks down cartilage, the smooth tissue that cushions the ends of bones in joints, leading to pain, stiffness, and progressive loss of mobility. It most frequently affects the knee, followed by the hand and hip [5].

The economic toll is staggering. Direct medical costs reach $65 billion annually [3]. Lost wages account for an additional $164 billion, with affected workers earning an average of $4,040 less per year and missing two more workdays annually than their unaffected peers [3]. Approximately one million knee and hip replacements are performed each year in the United States, at a cost of $15,000 to $70,000 per procedure [6]. In 2013, osteoarthritis was the second most costly health condition treated in U.S. hospitals [3].

Source: Global Burden of Disease Study 2021

Data as of Jan 1, 2023CSV

The burden is not evenly distributed globally. The United States has one of the highest osteoarthritis prevalence rates among peer nations at approximately 14% of the adult population, compared to 12.5% in Australia, 11.2% in Canada, and 10.6% in the United Kingdom [5]. The global average stands at 7.6%, with 595 million people affected worldwide as of 2020 — a 132% increase since 1990 [5]. Higher rates of obesity and older demographic profiles in Western economies are major drivers of the disparity [5].

What ARPA-H Is Funding

The NITRO program, launched in 2023 and awards announced in 2024, organizes its research across three technical areas [1][2]:

Technical Area 1 — Injectable Bone Regeneration. Three teams — Duke University, Washington University in St. Louis, and the University of Colorado Boulder — are developing minimally invasive therapies to repair the subchondral bone that supports damaged cartilage. The Duke-led team, headed by Dr. Benjamin Alman (chair of Duke's Department of Orthopaedic Surgery), proposes an injection that releases regenerative factors directly into bone tissue beneath injured cartilage [7]. The Washington University team is pursuing "smart cell" therapy, while Colorado Boulder is developing engineered therapeutic materials [1].

Technical Area 2 — Injectable Cartilage Regeneration. The same three teams are also developing injections to regenerate cartilage tissue within the joint. The Duke/UCLA/Boston Children's Hospital collaboration draws on developmental biology, targeting signaling pathways that drive cartilage formation during fetal growth [8]. Researchers have identified compounds in mouse models that repair articular cartilage and slow osteoarthritis progression, though the specific molecules have not been publicly named [8]. A systemic version — a drug administered intravenously rather than injected into a single joint — is also under development for patients with osteoarthritis in multiple joints [7].

Technical Area 3 — Biologically Grown Joint Replacements. Columbia University and Case Western Reserve University are pursuing the most ambitious goal: growing replacement knee joints from a patient's own stem cells and biomaterials. Columbia's NOVAJoint project, led by Dr. Clark T. Hung and Dr. Nadeen O. Chahine, received up to $38.95 million to develop a biocompatible, patient-specific knee joint [9]. The first prototypes are expected within two years, with preclinical and Phase I safety trials in years three through five [9]. Case Western is developing a modular alternative [1].

The Duke-led consortium received up to $33 million for its work across Technical Areas 1 and 2 [7]. UCLA Health, which will lead clinical trials for the Duke consortium, was awarded up to $12.3 million as part of the collaboration [10]. Phase I clinical trials across the program are anticipated to begin by 2028 [1].

A Decades-Long Funding Gap

The federal investment through NITRO, while substantial, arrives after decades of relative neglect. Osteoarthritis research has been chronically underfunded compared to other conditions of similar or lesser prevalence.

Source: NIH RePORT RCDC

Data as of Jan 1, 2024CSV

NIH categorical spending data shows the disparity in stark terms. In fiscal year 2024, Alzheimer's disease research received approximately $3.7 billion in NIH funding, and diabetes received approximately $1.2 billion [11]. Osteoarthritis received roughly $290 million — less than one-twelfth of Alzheimer's funding and about one-quarter of diabetes funding [11]. Even rheumatoid arthritis, which affects far fewer people (approximately 1.3 million Americans compared to osteoarthritis's 32.5 million), received $180 million [11].

A 2024 study published in The Lancet Regional Health — Americas found that osteoarthritis is funded at just 35% of the level that would be commensurate with its disease burden [12]. To reach proportional funding, osteoarthritis research investment would need to triple [12]. More broadly, musculoskeletal diseases — the leading cause of years lived with disability and the number-one condition associated with healthcare costs in the United States — receive less than 2% of the NIH's annual research budget [13]. Over the past decade, NIH funding for musculoskeletal conditions decreased by 17% even as the burden of disease grew at a rate second only to diabetes [13].

Source: OpenAlex

Data as of Jan 1, 2026CSV

Research output has nonetheless increased. Academic publications on osteoarthritis peaked at 44,561 papers in 2024, up from 9,443 in 2011 — a nearly five-fold increase driven largely by international research growth [14]. Whether this output translates into clinical progress depends on whether funding follows.

Why No Osteoarthritis Drug Has Ever Been Approved

The absence of any approved DMOAD is the central fact against which NITRO must be evaluated. Despite decades of investment from both industry and academia, every disease-modifying candidate has failed to clear regulatory hurdles [4].

A 2025 review of DMOAD clinical trials from 2010 to 2024 catalogued repeated failures across multiple drug classes [4]. Key obstacles include:

• The placebo effect. Osteoarthritis trials consistently show large placebo responses, making it difficult for experimental drugs to demonstrate statistically significant superiority [4].
• Assessment ambiguity. The FDA has not defined or implemented structural evaluating outcomes — measures of cartilage repair or bone change — to facilitate DMOAD approval. Without agreed-upon endpoints, proving a drug modifies the disease rather than merely masking symptoms is difficult [4].
• Biological complexity. Osteoarthritis involves degradation of cartilage, bone remodeling, inflammation, and nerve sensitization simultaneously. Targeting one pathway often fails to arrest the broader disease process [15].

The most recent high-profile setback was the FDA's rejection of a leading candidate, which rattled the already-thin osteoarthritis drug pipeline [16]. TissueGene-C (TG-C), a gene and cell therapy, is currently in Phase III trials and may become the first DMOAD to receive FDA approval — but results remain pending [4].

The historical attrition rate is severe. The cost of bringing a new drug to market rose from $92 million in 1979 to over $1.3 billion by 2018 [4]. For osteoarthritis specifically, no DMOAD candidate has survived the journey from identification to approval in the program's history. The NITRO program's emphasis on regenerative biology rather than traditional small-molecule pharmacology represents a different strategic bet, but the regulatory path remains unclear.

Who Pays, Who Benefits, and Who Might Not

NITRO is entirely federally funded through ARPA-H, an agency within the Department of Health and Human Services established in 2022 [1]. The program's five awardee teams are based at academic institutions — Duke, Washington University, University of Colorado Boulder, Columbia, and Case Western Reserve — with additional collaboration from UCLA and Boston Children's Hospital [1][7][9]. No pharmaceutical company partnerships have been publicly disclosed for the current research phase.

Conflicts of interest are difficult to assess at this stage. The researchers involved have not been flagged for financial conflicts in publicly available disclosures, but the standard academic-to-commercialization pipeline typically introduces industry partnerships as therapies approach clinical trials. The NITRO program's stated goal is not just to develop but to "commercialize" regenerative therapies [1], which implies eventual private-sector involvement.

The program has built in equity requirements. Clinical trials must enroll more than 50% women and must reflect the populations most affected by osteoarthritis [1]. This is a direct response to documented disparities.

Osteoarthritis does not affect all populations equally. Among racial and ethnic groups, Black Americans show higher rates of symptomatic and radiologically confirmed knee osteoarthritis, with more severe features at presentation [17]. Pain and disability are more pronounced in Black and Hispanic populations [18]. Yet white patients are significantly more likely to receive total joint replacement — the current gold-standard surgical treatment — than Black or Hispanic patients, even after controlling for insurance status, age, and socioeconomic factors [17].

Lower socioeconomic status compounds the problem. Patients with lower income and education levels are less likely to undergo joint replacement surgery, receive less provider education about their condition, and participate in fewer self-management programs [17]. Occupational exposure matters too: jobs requiring repetitive kneeling, squatting, and heavy lifting — disproportionately held by lower-income workers — increase osteoarthritis risk [18].

Whether NITRO's therapies will address these disparities depends on factors the research program alone cannot control: pricing, insurance coverage, and geographic availability.

The Commercialization Question

Even if one or more NITRO therapies succeed in Phase I trials by 2028, the path to patient access is long. A realistic timeline from Phase I through Phase II, Phase III, and FDA review typically spans 8 to 12 years [4]. That places the earliest possible approval in the mid-2030s, assuming no setbacks.

Cost is a major unknown. Current knee replacement surgery averages $29,300 but can exceed $70,000 depending on complications and geography [6]. Injectable regenerative therapies could in theory be cheaper than surgery, but biologics and cell-based therapies often carry high manufacturing costs. Columbia's living knee replacement project, if successful, would need to compete on cost with metal-and-plastic implants that have decades of manufacturing scale behind them [9].

Insurance coverage presents another barrier. Most health insurance plans, including Medicare, cover knee replacement when deemed medically necessary — but typically only after patients have exhausted conservative treatments [6]. New regenerative therapies would face their own coverage determinations, and insurers may require years of outcomes data before approving reimbursement. Patent exclusivity periods could also keep prices elevated during the initial years of availability.

Manufacturing scale is a particular concern for the Technical Area 3 projects. Growing patient-specific joints from individual stem cells is inherently more complex and expensive to scale than manufacturing standardized pharmaceuticals or devices. The Columbia team has acknowledged this challenge; their stated goal is to produce a "low-cost" replacement, but the economics of personalized biologics at scale remain unproven [9].

The Case for Cautious Optimism — and the Case Against

Supporters of the NITRO program point to several factors that distinguish it from previous efforts. First, ARPA-H's mandate is explicitly to fund high-risk, high-reward research that traditional NIH mechanisms and private industry tend to avoid [1]. Second, the program targets regeneration rather than symptom management — a fundamentally different approach from the small-molecule DMOADs that have failed in the past. Third, advances in developmental biology, stem cell science, and biomaterials engineering have opened therapeutic avenues that did not exist a decade ago [8][15].

The counterargument is grounded in the record. Osteoarthritis has a longer and more consistent history of therapeutic failure than almost any comparable chronic disease [4][16]. The placebo effect, biological complexity, and regulatory ambiguity that sank previous candidates have not been resolved. Animal models that show promise — including the Stanford research on 15-PGDH inhibition, which reversed cartilage loss in mouse knees [19] — frequently fail to translate to human outcomes. And the NITRO program's five-year timeline to Phase I is aggressive; Phase I trials test only safety, not efficacy.

There is also the question of opportunity cost. The $70 million-plus allocated to NITRO, while significant for osteoarthritis, represents a fraction of what would be needed to close the disease's funding gap. If NITRO produces promising but inconclusive results, the risk is that the field returns to its baseline state of underfunding and incremental progress, having consumed a decade and substantial resources.

What Comes Next

The NITRO program is now in its active research phase, with teams developing prototypes and preparing for preclinical studies. The first Phase I safety trials are expected by 2028 [1]. Results from those trials — likely available by 2029 or 2030 — will determine whether any of the three therapeutic approaches merit the larger, more expensive Phase II and III trials required for FDA approval.

For the 32.5 million Americans currently living with osteoarthritis, the practical near-term outlook has not changed. Available treatments remain limited to pain management (NSAIDs, corticosteroid injections, physical therapy) and, for advanced disease, joint replacement surgery [3]. No drug or therapy on the market can halt or reverse cartilage loss.

The NITRO program represents the federal government's clearest statement that osteoarthritis deserves the kind of coordinated research investment long reserved for conditions like Alzheimer's and cancer. Whether that statement translates into approved therapies reaching the patients who need them most — particularly lower-income and minority populations bearing a disproportionate burden — is a question that will take the better part of a decade to answer.